The presence of the blood–brain barrier may affect the action of ALK-tyrosine kinase inhibitor in the CNS, but there is insufficient evidence to support the hypothesis that the efficacy of chemotherapy and anti-ALK therapy is greater for ALK-positive histiocytosis in the lung than in the cerebrum. This evidence concerns the gene ALK and Histiocytosis.